The importance of securing strong, long-standing investigator networks with leading research hospitals and clinics is critical to the continued growth of the clinical trial environment in countries such as Taiwan, says Evon Hui, Head of Business Operations, East Asia. Over the past 15 years, George Clinical has cultivated an enviable network of MOUs that have […]
Read MoreGeorge Clinical, a leading clinical research organization (CRO) in the Asia-Pacific region, has gained recognition of the organization’s strong support of the Mandatory Provident Fund (MPF) legislation, and their provision of good MPF benefits. The Mandatory Provident Fund Schemes Authority (MPFA) awarded George Clinical their Good MPF Employer Award at a ceremony in Hong Kong […]
Read MoreGeorge Clinical welcomes the decision by the FDA to approve the delivery of CAR-T therapy in a partnership between Methodist Healthcare, and George Clinical Scientific Leader, Dr. Jason Chandler of West Cancer Center. Car-T therapies are at the cutting edge of treatment for a range of cancers. The recent announcement by the FDA, West Cancer […]
Read MoreBeijing, November 13, 2018 – George Clinical, a leading clinical research organization (CRO) in the Asia-Pacific region, has continued its involvement and collaboration with the Heart Health Research Center (HHRC), further developing the depth and quality of investigator networks. The HHRC, a collaborative initiative developed by Cardio Union, an emerging multi-disciplinary healthcare organization and the […]
Read More9 AUGUST, 2018 – (BEIJING) In another positive development in China’s rapidly evolving regulatory environment The China National Drug Administration (CNDA) has introduced a 60-day window for clinical trial approvals, mirroring US FDA protocols. The rules have taken immediate effect. “This new ruling has major implications for sponsors wishing to conduct China-only or multi-centre studies […]
Read More
In another encouraging step towards making China a leading destination for clinical drug trials, some critical developments were announced at The Executive Meeting of the State Council on the 12th April 2018. From 1 May 2018, the import tariff of all common drugs including anticancer drugs, alkaloids with anticancer effects and the imported Chinese patent […]
Read More
George Clinical, a leading full-service CRO in the US and Asia-Pacific region, is pleased to announce that Matthew Reabold, Sr. has been promoted to the Head of Business Development, USA. George Clinical, headquartered in Sydney, Australia, operates in fifteen countries around the world and has major operational hubs in the USA, East Asia, China, and India. Matthew, who is USA based, will […]
Read More
Sydney, Australia (May 2, 2017) – George Clinical, a leading full-service CRO in the Asia-Pacific region and Vector Oncology, a Memphis-based leader in oncology research and data analytics, formally announced today that George Clinical has acquired Vector Oncology’s CRO Division. Effective immediately, the transaction has the dual purpose of strengthening the ability of George Clinical […]
Read More
George Clinical is pleased to announce the receipt of their Hong Kong Wholesale Dealer licence issued by the Department of Health on the 3rd April. This licence represents a significant step forward in George Clinical’s operations in Hong Kong, allowing them to apply for a Certificate of Clinical Trial on behalf of the sponsor and […]
Read More
Taiwan sits, along with its smaller counterparts, Singapore and Hong Kong, as one of the gateway countries to running a clinical trial in China. Although Hong Kong’s regulatory ties are more formalized with China, than Taiwan, Taiwan has the right environment and population to make the possibility of greater regulatory cohesion with its giant neighbour, […]
Read More
